Sinovac Reports Unaudited Fourth Quarter and Preliminary Full Year 2009 Record Financial Results

  • Author: sinovac
  • Date: 2010-04-06
  • Source: sinovac
  • Pageview: 8945
Sinovac Reports Unaudited Fourth Quarter and Preliminary Full Year 2009 Record Financial Results
 
- Conference call scheduled Tuesday, April 6, 2010 at 9:00 a.m. EDT -
 
- Provides full year 2010 sales guidance of $67.1 million to $72.5 million -
 
    BEIJING, April 6 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month and preliminary twelve-month periods ended December 31, 2009.
 
    Financial Highlights
 
    -- Sales for the fourth quarter increased 194% to $36.4 million
    -- Sales for the twelve-month period grew 81% to $84.2 million
    -- Operating income for the fourth quarter rose 449% to $17.1 million
    -- Operating income for the twelve-month period increased 162% to $40.8
       million
    -- Net income attributable to shareholders for the fourth quarter rose
       275% to $8.9 million, with diluted EPS of $0.21
    -- Net income attributable to shareholders for the full year 2009 grew
       149% to $20.0 million, with diluted EPS of $0.46
    -- Cash and cash equivalents at December 31, 2009 were $75.0 million
 
    Business Highlights
 
    -- In February 2010, Sinovac's subsidiary, Sinovac Beijing, completed the
       acquisition of production facilities, including land use right and five
       buildings with a total area of 32,322 square meters on a parcel of land
       of 29,021 square meters, located in Changping District, Beijing. The
       Company plans to set up two new production lines, with a combined
       annual production capacity of approximately 40 million doses, to
       manufacture the vaccine for enterovirus 71 (EV 71), which causes hand,
       foot, and mouth disease (HFMD), as well as its currently marketed flu
       vaccines.
 
    -- In February 2010, the Company closed a public common share offering. A
       total of 11,500,000 common shares, including 1,500,000 common shares
       pursuant to the full exercise of the underwriters' over-allotment
       option, were issued at $5.75 per share. The Company received net
       proceeds of approximately $62.0 million, after deducting underwriting
       discounts, commissions and offering expenses.
 
    -- In January 2010, Sinovac established Sinovac Dalian, which focuses on
       the research, development, manufacturing and commercialization of
       vaccines, such as rabies, chickenpox, mumps and rubella vaccines for
       human use. Sinovac will manufacture live attenuated vaccines and vero
       cell cultured vaccines at the production facilities of Sinovac Dalian.
 
    -- In January 2010, Sinovac received its fifth purchase order for its H1N1
       vaccine, Panflu.1(TM), from China's Ministry of Industry and
       Information Technology (MIIT) for the national purchase plan of total
       8.57 million doses. Under this purchase order, Sinovac is required to
       deliver an additional 2.33 million doses of Panflu.1(15ug/0.5ml) to
       the Chinese Central Government, and the remaining 6.24 million doses
       will be stockpiled in our warehouse. Out of 2.33 million order, 0.18
       million doses were delivered in 2009 required by the government under
       emergency. The remaining 2.15 million doses are required to deliver
       before March 15, 2010. However, the delivery was postponed due to the
       delayed completion of batch release process within NICPBP. The delivery
       schedule shall be re-confirmed after the products are released by
       NICPBP in second quarter. The remaining 6.24 million doses of this
       order will be stockpiled in the Company's warehouse. In aggregate,
       Sinovac has received Panflu.1 orders for a total of 20.97 million doses
       from the MIIT after the two local CDC subsequently decreased the
       ordered quantity by 90,000 doses. As previously disclosed, Sinovac has
       delivered 10.23 million doses of Panflu.1 in 2009. Out of 10.23 million
       doses, we replaced 0.15 million doses with longer shelf life in 2010.
       Therefore, in 2009, we recognized the revenue of 10.08 million doses of
       H1N1. In 2010, there will be 2.15 million doses will be delivered and
       8.74 million doses will be stockpiled in the Company's warehouse.
       Revenues of 8.74 million doses will not be recognized until 2011, when
       the shelf life expires, unless the government requests us to deliver
       prior to that depending on the outbreak of the H1N1 disease in China.
 
    -- In December 2009, China's State Food and Drug Administration (SFDA)
       accepted the Company's application to commence human clinical trials
       for its vaccine against human EV 71, which causes HFMD. This is the
       first clinical trial application submitted in China for the EV71
       vaccine. No vaccine or antiviral treatment is currently available for
       HFMD worldwide.
 
 
    Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "Sinovac had a very productive year executing on its core strategy to support continued growth by simultaneously expanding its pipeline of novel products and increasing capacity to meet rising demand for our world class vaccines. We believe that Sinovac has established itself as a company that can strategically deliver steady and robust growth. Going into 2009 with a net revenue CAGR of 74.0% between 2006 and 2008, we demonstrated this past year that we can exceed this growth and maintain our strategy even as we lead in development to address a global crisis."
    Mr. Yin concluded, "In the coming year, we will continue to work to position ourselves as a well-rounded and diversified vaccine company with near-term and long-term opportunities for growth. Sinovac has taken steps to increase its production capacity to meet the additional anticipated demand as we continue to expand the markets for our commercialized products. We see a substantial opportunity for Healive, in particular, as we take advantage of the additional opportunities presented by the changing landscape of the public and private markets in China. We will seek to continue to develop our novel products, such as our EV 71 vaccine, pneumococcal conjugated vaccine, rabies vaccine, HIB vaccine, meningitis vaccine, Japanese Encephalitis vaccine, chickenpox (varicella) vaccine, mumps vaccine and rubella vaccine."
 
    Financial Review for Three Months Ended December 31, 2009
    During the fourth quarter of 2009, sales were $36.4 million, up 194% from $12.4 million in the fourth quarter of 2008. Fourth quarter 2009 sales included the full recognition of MIIT's purchase of 10.08 million doses of Sinovac's Panflu.1 in December 2009, as part of China's national purchase plan. The sales breakdown by product was as follows.
 
 
 
                                         Three months           Three months     
                                                ended                  ended            
                                             December               December        
                                             31, 2009               31, 2008
        
    Healive                                $4,906,316             $9,763,218
    Bilive                                  1,459,224                191,218
    Anflu                                   1,894,540              2,405,367
    Panflu.1 (H1N1)                        28,127,991                     --
    Total                                 $36,388,071            $12,359,803
 
 
    Gross profit for the fourth quarter 2009 was $25.2 million, with a gross margin of 69%, compared to $7.7 million and a gross margin of 63% for the same period of 2008.  The gross margin for the fourth quarter of 2009 increased due to increased production efficiencies as Anflu and Panflu.1 utilized the same production line and lower product returns in the fourth quarter of 2009. 
    Total operating expenses for the fourth quarter of 2009 were $8.2 million, compared to $4.6 million in the comparative period in 2008. Selling, general and administrative expenses for the fourth quarter of 2009 were $6.3 million, compared to $4.1 million in the same period of 2008. SG&A expenses as a percentage of fourth quarter 2009 sales decreased to 17% from 33% during the fourth quarter of the prior year. The lower SG&A expenses as a percentage of revenue resulted from the increased economies of scale associated with the significant sales growth.
    Net research and development expenses for the fourth quarter 2009 were $1.6 million, compared to $359,000 in the same period of 2008. The increased R&D expenses in the fourth quarter of 2009 were mainly related to the continued development of the EV 71 vaccine and pneumococcal conjugated vaccine.
    Fourth quarter 2009 operating income was $17.1 million, compared to operating income of $3.1 million in the fourth quarter of the prior year. The higher operating income in the current year quarter was attributable to the significant sales growth and the greater economies of scale.
    Net income for the fourth quarter of 2009 included $1.06 million in interest and other income, $37,000 million of interest and financing expense and $4.7 million in income tax expenses. Net income for the same period of 2008 included$327,000 of interest and other income, $46,000 million of interest and financing expense, and $284,000 of income tax credit. Net income attributable to shareholders for fourth quarter of 2009 was $8.9 million, or $0.21 per diluted share, up 275% compared to net income attributable to shareholders of $2.4 million, or $0.06 per diluted share, in the same period of 2008.
    As of December 31, 2009, Sinovac's cash and cash equivalents totaled $75.0 million, compared to $32.9 million as of December 31, 2008. The increase in cash and cash equivalents primarily reflected the Company's operating activities cash inflow of $48.4 million.
 
    Financial Review for Twelve Months Ended December 31, 2009
    During the twelve months ended December 31, 2009, sales were $84.2 million, up 81% from $46.5 million for the same period in 2008. Sinovac recorded strong sales growth in the second, third and fourth quarters of 2009, along with the full recognition of MIIT's purchase of 10.08 million doses of Sinovac's Panflu.1 in December 2009, as part of China's national purchase plan.
    Sales of Healive and Anflu to the public market accounted for 19% of total sales for the twelve months ended December 31, 2009. The sales breakdown by product was as follows.
 
 
                                                  2009               2008
                                              
    Healive                                   $33,016,191        $40,776,056
    Bilive                                      6,226,710          1,657,171
    Anflu                                      15,204,948          4,063,677
    Panflu (H5N1)                                  64,318                 --
    Panflu.1 (H1N1)                            29,685,015                 --
    Total                                     $84,197,182        $46,496,904
 
 
    Gross profit for the 2009 twelve-month period was $64.1 million, with a gross margin of 76%, compared to $36.6 million and a gross margin of 79% for the prior year period. The 2009 gross margin was adversely affected by increased sales to the public market that resulted in a lower price compared to the private market, especially for Panflu.1, given that government procurement sales grew in 2009.
    Total operating expenses for the twelve months of 2009 were $23.3 million, compared to $21.0 million in the comparative period in 2008. Selling, general and administrative expenses for the full year 2009 were $18.2 million, compared to $17.5 million in the prior year period. SG&A expenses as a percentage of sales decreased to 22% from 38% in the comparative period, due to the economies of scale achieved through increased sales as well as a higher portion of sales to the Chinese government, particularly sales of Healive and Panflu.1, which have lower selling expenses attributed to such sales. Net research and development expenses for the twelve months of 2009 were $4.4 million, compared to $2.8 million in the prior year period.
    Operating income for the twelve months ended December 31, 2009 was $40.8 million, compared to an operating income of $15.6 million in the prior year period. The year-over-year increase reflected both increased 2009 sales associated with Panflu.1 and lower operating expenses from sales to public market.
    Net research and development expenses for the twelve months ended December 31, 2009 were $4.41 million, compared to $2.77 million in the same period of 2008, which is an increase of 59%. The increased R&D expenses in the period were mainly related to the continued development of our pipeline product. And the company expects to keep investing in R&D to fuel the future growth.
    Net income for the twelve months of 2009 included $1.3 million in interest and other income, $534,000 of interest and financing expense, and $11.1 million in income tax expenses. Net income for the same period of 2008 included $291,000 of interest and other income, $702,000 of interest and financing expense, and $3.0 million of income tax expense. Net income attributable to shareholders for the twelve months of 2009 was $20.0 million, or $0.46 per diluted share, compared to net income of $8.0 million, or $0.19 per diluted share, in the same period of 2008.
 
    Recent Developments
    In November 2009, Sinovac entered into a joint venture agreement with Dalian Jin Gang Group to form Sinovac Dalian. Sinovac Dalian was established in January 2010 to focus on the research, development, manufacturing and commercialization of vaccines, such as rabies, chickenpox, mumps and rubella vaccines for human use. And in February 2010, Sinovac's subsidiary, Sinovac Beijing, completed the acquisition of production facilities, including land use right and buildings, located in Changping District, Beijing. Sinovac plans to build up capacity for it seasonal flu vaccine and pipeline products.
    In 2009, Sinovac's research and development program was restructured, pursuant to which the Company established an R&D team in Beijing to better utilize its scientific and personnel resources. Sinovac's R&D program is equipped with world-class facilities that provide a platform for about 50 scientists conducting vaccine research and development. Currently, eight major R&D projects are underway.
    In 2009, Healive sales to the public market represented 43.31% of total Healive sales. The significant portion of sales from the public market, particularly from Sinovac's largest market segment of children 18 months, resulted from Sinovac's high value-added services to its customers. In juxtaposition to the growth in the public market for the hepatitis A vaccine in 2009, the demand in the private market for the hepatitis A vaccine for the 18 month population has decreased as that segment is now covered by the public market vaccination program. In 2010, it is projected that the public market demand for the hepatitis A vaccine will continue to gradually increase. Therefore, Sinovac is well positioned to further expand its market share in the public market in 2010 and, at the same time, expand its sales to a broader target population encompassing a wider scope of age groups in the private market.
    As we indicated previously, the public market purchase of hepatitis A vaccine will be fully implemented in China in 2010 as per Chinese government plan. However, in the first quarter of 2010, the public market is not open up enough as many local CDCs are still in the preparation for the tendering process, which we expect, will take off from the 2nd quarter of 2010.
    Sinovac has previously entered into distribution agreements with local market distribution partners to register the Company's vaccines in Philippines, Mexico, India, Hong Kong and Korea. The process to register the vaccines and receive the regulatory approval is underway in the majority of those countries.  Sinovac expects selling activities in some of those countries to commence in 2011 at the earliest.
 
    2010 Guidance
    In China, the public perceptions of vaccines have been impacted by recent media reports. Earlier this year, the media reported on improper storage of vaccines by a distributor in China's Shanxi province, which might have linked to a few cases of serious adverse events. Although Sinovac was not involved with both events, we believe that these issues may adversely impact the public's perceptions of vaccine safety and thus may reduce vaccine administration by the Chinese government. Therefore, we expect our organic business may be impacted in the short-term. But we still expect our business to grow gradually and the at the same time, the Company will increase investment on vaccine R&D and capacity buildup for existing products and pipeline product in order to maintain the sustainable growth in the long-term. Furthermore, we believe that our core competencies inclusive of proven R&D capability, manufacturing and distribution capabilities position us to capitalize on potential partnership or acquisition opportunities during this period.
    For the full year 2010, the Company expects sales of its non-H1N1 vaccines to increase by approximately 10% to 20%, compared to $54.5 million in non-H1N1 vaccines sales in 2009.  It is anticipated that the 2.15 million doses of Panflu.1 purchased by the government will be delivered to the local CDC and the remaining 8.74 million doses of Panflu.1 will be stockpiled by the government in the Company's warehouse facility in 2010.  And we expect that the revenue of these 8.74 million H1N1 vaccine will be recognized in one year time when it's expired if not being delivered before it shelf life is ended. Total 2010 sales, including recognized revenue for the 2.15 million doses of Panflu.1, are expected to be in the range of approximately $67.1 million to $72.5 million.
    In 2010, the Company expects to advance the clinical development of its pipeline products as follows: (i) to commence clinical trials in China for its EV71 vaccine and Japanese encephalitis vaccine upon receiving the approval of clinical trial application from SFDA in 2010; (ii) to file the clinical trial application with the SFDA for its pneumococcal conjugate vaccine; and (iii) to file clinical trial applications with the SFDA for three products (haemophilus influenzae type b (Hib) vaccine, mumps vaccine, and rubella vaccine) under development at Sinovac Dalian. And in the year, we will keep executing our business plan to increase our potential capacity through the plant transformation of facilities in Dalian JV and Changping facility to prepare for the industrialization of our pipeline products to fuel the future growth.
 
    Conference Call Details
    The Company will host a conference call on Tuesday, April 6, 2010 at 9:00 a.m. EDT (9:00 p.m. China Standard Time) to review the Company's financial results for the fourth quarter and year ended December 31, 2009 and provide an update on recent corporate developments. To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). A replay of the call will be available from 12:00 p.m. EDT on April 6, 2010 until April 20, 2010. To access the replay, please dial 1-877-660-6853 (USA) or 1-201-612-7415 (international) and reference the account number 3055 and the access code 348065. A live audio webcast of the call will also be available from the Investors section on the corporate web site at http://www.sinovac.com . A webcast replay can be accessed on the corporate website beginning April 6, 2010 and the replay will remain available for 30 days.
 
    About Sinovac
    Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (seasonal influenza), Panflu(TM) (pandemic influenza (H5N1)), and Panflu.1(TM) (pandemic influenza A (H1N1)). Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, pneumococcal infection, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.
 
    Safe Harbor Statement
    This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any
forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
 
    For more information, please contact:
 
     Helen G. Yang
     Sinovac Biotech Ltd.
     Tel:   +86-10-8289-0088 x9871
     Fax:   +86-10-6296-6910
     Email: info@sinovac.com
 
    Investors:
     Amy Glynn/Stephanie Carrington
     The Ruth Group
     Tel:   +1-646-536-7023/7017
     Email: aglynn@theruthgroup.com
            scarrington@theruthgroup.com
 
    Media:
     Janine McCargo
     The Ruth Group
     Tel:   +1-656-536-7033
     Email: jmccargo@theruthgroup.com
 
SINOVAC BIOTECH LTD.
Consolidated Balance Sheets
December 31, 2009 and 2008
(Expressed in U.S. Dollars)
 
 
 
Current assets
$
December 31,2009
$
December 31,2008
Cash and cash equivalents
74,953,212
32,894,102
Restrict cash
64,400
-
short term investment
7,313,149
-
Accounts receivable
24,540,134
19,486,596
Inventories
9,599,118
6,486,351
Income tax refundabele
-
348,018
Prepaid expenses and deposits
466,346
933,297
DIT asset - current
 
1,375,174
 
1,189,831
Total current assets
118,311,533
61,338,195
Property, plant and equipment
22,306,688
19,262,099
Deferred tax asset
520,077
569,937
License and permit
695,109
1,090,477
Long-term inventories
2,642,734
942,514
Total   assets
$
144,476,141
$
83,203,222
Current liabilities
Loans payable
$
17,697,821
$
8,024,277
Income tax payable
6,413,734
-
Accounts payable and accrued liabilities
17,784,509
11,909,037
Deferred revenue
5,386,749
-
Deferred tax liability
1,398,123
-
Due to related parties
-
46,971
Dividends payable to non-controlling interest shareholder of Sinovac Beijing
-
115,677
Deferred research grants
$
1,331,476
$
1,182,703
-
Total current liabilities
50,012,412
21,278,665
Deferred revenue - H5N1
6,942,824
-
Long term payable
407,794
-
Loans payable
-
2,188,439
Deferred government grants
2,646,669
2,836,994
Total liabilities
 
60,009,699
 
26,304,098
Commitments and contingencies
Equity
Preferred stock
Common stock
42,585
42,894
Subscriptions received
-
Additional paid in capital
42,533,876
41,629,506
Accumulated other comprehensive income
4,225,196
4,143,225
Dedicated reserves
9,863,251
5,549,684
Retained earning(accumulated deficit)
13,993,287
(1,651,534)
Total stockholder's equity
 
70,658,195
 
49,713,775
Non-controlling interest
13,808,247
7,185,349
Total equity
84,466,442
56,899,124
Total liability and equity
$
144,476,141
$
83,203,222
 
 
 
SINOVAC BIOTECH LTD.
 Consolidated Statements of Income and Comprehensive Income
Three Months and twelve Months ended
 December, 31 2009 and 2008 
 (Expressed in U.S. Dollars)
 Three months ended December 31
 Twelve months ended December 31
 
 
2009
 
2008
 
2009
 
2008
 Sales
36,388,071
       12,359,803
84,197,182
         46,496,904
 Cost of sales(exclusive of depreciation of land use right and amortization of licenses and permits of $104,786 (2008-$208,998)for three months and $418,867 (2008-$411,573)for twelve months)
 $
11,177,110
 $
4,615,674
 $
20,063,361
 $
9,936,341
 Gross profit
25,210,961
7,744,129
64,133,821
36,560,563
 Selling, general and administrative expenses
6,319,939
         4,054,222
18,247,818
         17,462,674
 Research and development expenses - net of $(10,425) (2008- $162,064) for three months and $251,436 (2008- $310,022) for twelve months in government research grants
1,652,609
             358,664
4,405,618
           2,767,409
 Depreciation of property, plant and equipment and amortization of licenses and permits
180,861
223,502
692,696
749,619
 Total operating expenses
 
8,153,409
 
4,636,388
 
23,346,132
 
20,979,702
 Operating income
17,057,552
3,107,741
40,787,689
15,580,861
 Interest and financing expenses 
36,894
               45,859
(534,455)
(701,637)
 Interest income and other income 
 
1,057,221
 
             327,248
 
1,300,672
 
              290,563
 Income before income taxes and non-controlling interest 
18,151,667
3,480,848
41,553,906
15,169,787
 Income taxes -current
(4,851,796)
788,445
(9,878,698)
(3,441,168)
 Income taxes -deferred
              137,605
(504,450)
(1,261,823)
487,011
 Consolidated net income
 
13,437,476
 
3,764,843
 
30,413,385
 
12,215,630
Less:income attributable to the non-controlling interest
 
(4,537,782)
 
(1,390,704)
 
(10,454,997)
 
(4,205,407)
 Net Income attributable to stockholders
 $
8,899,694
 $
2,374,139
 $
19,958,388
 $
8,010,223
 Net Income
 $
13,437,476
 $
3,764,843
 $
30,413,385
 $
12,215,630
Other comprehensive income
Foreign currency translation adjustment
 
8,745
 
(89,932)
 
99,473
 
2,269,024
Total comprehensive income
13,446,221
3,674,911
30,512,858
14,484,654
Less: comprehensive income attributable to non-controlling interest
4,540,048
1,398,004
10,472,499
4,287,662
Comprehensive income attributable to stockholders
 $
8,906,173
 $
2,276,907
 $
20,040,359
 $
10,196,992
 Earning (loss) per share - basic 
0.21
                    0.06
0.47
0.19
                                          - diluted
0.21
0.06
0.46
0.19
 Weighted average number of shares of
   Basic
 $
42,585,044
 $
       42,892,954
 $
42,580,945
 $
42,426,703
   Diluted
 $
43,853,618
 $
42,892,954
 $
42,975,007
 $
42,450,606
 
 
r
SINOVAC BIOTECH LTD.
 Consolidated Statements of Cash Flows
Three Months and twelve Months ended
 December, 31 2009 and 2008 
 (Expressed in U.S. Dollars)
Three Months ended December 31
Twelve Months ended December 31
 Cash flows from (used in) operating activities
2009
2008
2009
2008
  Net income for the period
 $
13,437,476
 $
3,764,843
 $
30,413,385
 $
12,215,630
   Adjustments to reconcile net income to net cash :
    Provided by Operating Activities
   - deferred income taxes
(137,605)
504,450
1,261,823
(487,011)
   - write-off equipment and loss on disposal 
176,386
123,987
169,678
126,236
   - stock-based compensation
114,665
16,635
422,860
66,542
   - provision for doubtful debts
(699,393)
(1,944,595)
17,744
23,612
   - Inventory provision
593,451
962,772
593,451
962,772
   - depreciation of property, plant and equipment, and 
     amortization of licenses and permits
845,075
470,373
2,239,139
1,768,687
   - deferred government grant recognized in income
(1,119,054)
(79,669)
(1,119,054)
(79,669)
   - research and development expenditures qualified for 
     government grant
10,425
(162,345)
(251,436)
(310,022)
   - accounts receivable
13,069,054
7,284,649
(5,019,696)
(1,366,183)
   - inventories
3,813,839
(406,323)
(5,384,946)
(4,341,079)
   - prepaid expenses and deposits
410,684
40,618
468,782
229,407
   - income tax refundable
3,449,433
(342,617)
6,758,750
(342,617)
   - long term payable,deferred revenue and advances 
     from customers
2,930,556
                 -  
12,722,284
                  -  
   - accounts payable and accrued liabilities
2,756,301
64,969
5,118,740
2,038,531
 Net cash used in operating activities
 
    39,651,293
 
    10,297,747
 
    48,411,504
 
     10,504,836
 Cash flows from (used in) financing activities
   - loan proceeds
1,613,192
6,474,698
17,687,473
8,617,904
   - loan repayment
(5,848,066)
(3,609,576)
(10,232,422)
(7,181,586)
   - proceeds from shares issued
                 -  
(428,234)
697,320
9,814,709
   - subscriptions received 
4,035
                 -  
4,035
                  -  
   - government grants for R&D
1,147,531
169,176
1,318,857
383,497
   - share bought back
                 -  
                 -  
(335,831)
(368,323)
   - dividend paid to non-controlling shareholders 
     of Sinovac Beijing
                 -  
                 -  
(3,846,501)
(2,947,877)
 Net cash provided by (used in) financing activities
 
(3,083,308)
 
     2,606,064
 
      5,292,931
 
      8,318,324
 Cash flows from (used in) investing activities
   - restricted cash
(64,400)
725
(64,400)
                  -  
   - proceed from disposal of equipment
                 -  
16,848
                 -  
16,848
   - short-term investment
(7,308,873)
                 -  
(7,308,873)
                  -  
   - acquisition of property, plant and equipment
(839,621)
(693,034)
(4,320,065)
(3,976,458)
 Net cash provided used in investing activities
 
(8,212,894)
 
(675,461)
 
(11,693,338)
 
(3,959,610)
 Exchange gain on cash and equivalents
          18,332
        113,252
          48,013
         959,055
 Increase in cash and cash equivalents
    28,373,423
#
    12,341,602
    42,059,110
     15,822,605
  
 Cash and cash equivalents, beginning of period
    46,579,789
    20,552,500
    32,894,102
     17,071,497
                 -  
 Cash and cash equivalents, end of period
 $
    74,953,212
 $
    32,894,102
 $
    74,953,212
 $
     32,894,102
 Supplemental disclosure of cash flow information:
 Cash paid in interests
 $
298,855
 $
147,411
 $
914,546
 $
604,076
 Cash paid in income tax
 $
1,348,862
 $
1,469,261
 $
3,066,447
 $
4,281,391
 
   
Bookmark and Share

Copyright © 2001-2015 Sinovac Biotech Ltd. All Rights Reserved.

Add: No. 39 Shangdi Xi Road, Haidian District, Beijing, P.R.C. 100085 Supported by elongtian